Metabolic Communication by SGLT2 Inhibition
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood.
METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia.
RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell-derived engineered heart tissue.
CONCLUSIONS: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.
| Errataetall: |
CommentIn: Nat Rev Nephrol. 2024 Mar;20(3):155. - PMID 38291107 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Circulation - 149(2024), 11 vom: 12. März, Seite 860-884 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 04.04.2024 published: Print-Electronic CommentIn: Nat Rev Nephrol. 2024 Mar;20(3):155. - PMID 38291107 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCULATIONAHA.123.065517 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366436414 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366436414 | ||
| 003 | DE-627 | ||
| 005 | 20240404234526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.123.065517 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM366436414 | ||
| 035 | |a (NLM)38152989 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Billing, Anja M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic Communication by SGLT2 Inhibition |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Rev Nephrol. 2024 Mar;20(3):155. - PMID 38291107 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood | ||
| 520 | |a METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia | ||
| 520 | |a RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell-derived engineered heart tissue | ||
| 520 | |a CONCLUSIONS: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a gastrointestinal microbiome | |
| 650 | 4 | |a heart | |
| 650 | 4 | |a kidney | |
| 650 | 4 | |a metabolome | |
| 650 | 4 | |a plasma | |
| 650 | 4 | |a proteome | |
| 650 | 4 | |a sodium-glucose transporter 2 inhibitors | |
| 650 | 4 | |a uremic toxins | |
| 650 | 4 | |a urine | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a 4-cresol sulfate |2 NLM | |
| 650 | 7 | |a 56M34ZQY1S |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 |2 NLM | |
| 650 | 7 | |a Uric Acid |2 NLM | |
| 650 | 7 | |a 268B43MJ25 |2 NLM | |
| 650 | 7 | |a Tryptophan |2 NLM | |
| 650 | 7 | |a 8DUH1N11BX |2 NLM | |
| 650 | 7 | |a Uremic Toxins |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 650 | 7 | |a Sodium |2 NLM | |
| 650 | 7 | |a 9NEZ333N27 |2 NLM | |
| 650 | 7 | |a Cresols |2 NLM | |
| 650 | 7 | |a Sulfuric Acid Esters |2 NLM | |
| 700 | 1 | |a Kim, Young Chul |e verfasserin |4 aut | |
| 700 | 1 | |a Gullaksen, Søren |e verfasserin |4 aut | |
| 700 | 1 | |a Schrage, Benedikt |e verfasserin |4 aut | |
| 700 | 1 | |a Raabe, Janice |e verfasserin |4 aut | |
| 700 | 1 | |a Hutzfeldt, Arvid |e verfasserin |4 aut | |
| 700 | 1 | |a Demir, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Kovalenko, Elina |e verfasserin |4 aut | |
| 700 | 1 | |a Lassé, Moritz |e verfasserin |4 aut | |
| 700 | 1 | |a Dugourd, Aurelien |e verfasserin |4 aut | |
| 700 | 1 | |a Fallegger, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Klampe, Birgit |e verfasserin |4 aut | |
| 700 | 1 | |a Jaegers, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Kravtsova, Olha |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo-Masip, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Palermo, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Fenton, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Hoxha, Elion |e verfasserin |4 aut | |
| 700 | 1 | |a Blankenberg, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Kirchhof, Paulus |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Tobias B |e verfasserin |4 aut | |
| 700 | 1 | |a Laugesen, Esben |e verfasserin |4 aut | |
| 700 | 1 | |a Zeller, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Chrysopoulou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Saez-Rodriguez, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Magnussen, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Eschenhagen, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Staruschenko, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Siuzdak, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Poulsen, Per L |e verfasserin |4 aut | |
| 700 | 1 | |a Schwab, Clarissa |e verfasserin |4 aut | |
| 700 | 1 | |a Cuello, Friederike |e verfasserin |4 aut | |
| 700 | 1 | |a Vallon, Volker |e verfasserin |4 aut | |
| 700 | 1 | |a Rinschen, Markus M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 149(2024), 11 vom: 12. März, Seite 860-884 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2024 |g number:11 |g day:12 |g month:03 |g pages:860-884 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065517 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2024 |e 11 |b 12 |c 03 |h 860-884 | ||